RT Journal Article
T1 Cost of Hospitalizations due to Exacerbation in Patients with Non-Cystic Fibrosis Bronchiectasis.
A1 de-la-Rosa-Carrillo, David
A1 Navarro-Rolon, Annie
A1 Giron-Moreno, Rosa Maria
A1 Montull-Veiga, Beatriz
A1 Olveira-Fuster, Casilda
A1 Padilla-Galo, Alicia
A1 Prados-Sanchez, Concepcion
A1 Quintana-Gallego, Esther
A1 Sibila-Vidal, Oriol
A1 Celorrio-Jimenez, Nuria
A1 Ruiz-Peña, Antonio
A1 Torres-Marti, Antoni
A1 Aviles-Ingles, Maria Jesus
A1 Blanco-Aparicio, Marina
A1 Garcia-Clemente, Marta
A1 Golpe-Gomez, Rafael
A1 Gomez-Bonilla, Ainhoa
A1 Gomez-Gonzalez, Cristina
A1 Leal-Arranz, Maria Victoria
A1 Minguez-Clemente, Patricia
A1 Lopez-Muñiz, Belen
A1 Maiz-Carro, Luis
A1 Pando-Sandoval, Ana
A1 Rodriguez-Hermosa, Juan Luis
A1 Uranga-Echeverria, Ane
A1 Nuñez-Ares, Ana
A1 Lopez-Roldan, Lorena
A1 Abellan-Martinez, Carmen
A1 Martinez-Garcia, Abel Jesus
A1 Michel-de-la-Rosa, Francisco Javier
A1 Godoy-Mayoral, Raul
A1 Martinez-Garcia, Miguel Angel
K1 Antibiotic treatment
K1 Bronchiectasis
K1 Costs
K1 Hospitalization
K1 Pseudomonas aeruginosa colonization
AB Knowing the cost of hospitalizations for exacerbation in bronchiectasis patients is essential to perform cost-effectiveness studies of treatments that aim to reduce exacerbations in these patients. To find out the mean cost of hospitalizations due to exacerbations in bronchiectasis patients, and to identify factors associated with higher costs. Prospective, observational, multicenter study in adult bronchiectasis patients hospitalized due to exacerbation. All expenses from the patients' arrival at hospital to their discharge were calculated: diagnostic tests, treatments, transferals, home hospitalization, admission to convalescence centers, and hospitals' structural costs for each patient (each hospital's tariff for emergencies and 70% of the price of a bed for each day in a hospital ward). A total of 222 patients (52.7% men, mean age 71.8 years) admitted to 29 hospitals were included. Adding together all the expenses, the mean cost of the hospitalization was EUR 5,284.7, most of which correspond to the hospital ward (86.9%), and particularly to the hospitals' structural costs. The adjusted multivariate analysis showed that chronic bronchial infection by Pseudomonas aeruginosa, days spent in the hospital, and completing the treatment with home hospitalization were factors independently associated with a higher overall cost of the hospitalization. The mean cost of a hospitalization due to bronchiectasis exacerbation obtained from the individual data of each episode is higher than the cost per process calculated by the health authorities. The most determining factor of a higher cost is chronic bronchial infection due to P. aeruginosa, which leads to a longer hospital stay and the use of home hospitalization.
PB S. Karger AG
YR 2018
FD 2018-07-11
LK http://hdl.handle.net/10668/12701
UL http://hdl.handle.net/10668/12701
LA en
NO de la Rosa Carrillo D, Navarro Rolon A, Girón Moreno RM, Montull Veiga B, Olveira Fuster C, Padilla Galo A, et al. Cost of Hospitalizations due to Exacerbation in Patients with Non-Cystic Fibrosis Bronchiectasis. Respiration. 2018;96(5):406-416
DS RISalud
RD Apr 7, 2025